The Thailand Food and Drug Administration approved Antengene's (HKG:6996) new drug application for its selinexor drug, according to a Monday filing with the Hong Kong Stock Exchange.

The approvals are for the combination of selinexor with bortezomib and dexamethasone for multiple myeloma patients with at least one prior therapy.

The drug is also indicated for combination with dexamethasone for multiple myeloma patients with at least four prior therapies and resistance to at least two proteasome inhibitors, two immunomodulatory agents, and an anti-CD38 monoclonal antibody, the filing said.

Shares closed 4% higher during Monday's trading.

Price (HKD): $0.57, Change: $+0.020, Percent Change: +3.64%